Seema Nanda

Learn More
We consider a mathematical model of drug therapy for chronic myelogenous leukemia for an individual patient over a fixed time horizon. The disease dynamics are given by a system of ordinary differential equations that describe the interaction between naive T cells, effector T cells and leukemic cancer cells in a hypothetical patient. We introduce two drug(More)
B cell chronic lymphocytic leukemia (B-CLL) is known to have substantial clinical heterogeneity. There is no cure, but treatments allow for disease management. However, the wide range of clinical courses experienced by B-CLL patients makes prognosis and hence treatment a significant challenge. In an attempt to study disease progression across different(More)
  • 1